BPC-157 / TB-500 Blend 10/10mg: Research Overview
The BPC-157 / TB-500 Blend combines two of the most extensively studied healing peptides into a single lyophilized preparation. Body Protection Compound-157 (BPC-157) is a stable pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein in human gastric juice. TB-500 corresponds to the N-terminal fragment (residues 17-23) of thymosin beta-4, the most abundant G-actin sequestering peptide in eukaryotic cells. Each component operates through distinct mechanisms — BPC-157 drives angiogenesis via VEGF/eNOS/NO signaling, while TB-500 facilitates cell migration through G-actin sequestration and cytoskeletal remodeling. This 10/10mg blend is supplied exclusively for in vitro laboratory research.
Molecular Background & Mechanism of Action
BPC-157 upregulates VEGF expression and eNOS activation, driving new blood vessel formation essential for tissue regeneration[1][2]. It is remarkably stable in gastric acid and maintains activity without a carrier protein. TB-500 retains the actin-binding activity of full-length Tβ4, maintaining a pool of monomeric G-actin for rapid mobilization during cell migration, wound closure, and tissue remodeling[3][4]. The combination simultaneously addresses vascular supply (BPC-157) and cellular motility (TB-500), the two rate-limiting processes in wound repair.
Preclinical Evidence
BPC-157 has demonstrated consistent pro-healing effects in rodent models of tendon transection, significantly improving functional recovery and biomechanical strength[1]. Thymosin beta-4 studies show accelerated re-epithelialization and increased collagen synthesis in dermal wounds[3][5]. The rationale for combining these peptides derives from their non-overlapping mechanism profiles — BPC-157’s angiogenic activity establishes vascular infrastructure while TB-500’s actin-remodeling enables cellular migration to populate wound beds.
Research Applications
- Wound Healing Models: Synergistic angiogenesis and cell migration in dermal excision, incisional, and burn wound models.
- Tendon and Ligament Repair: Fibroblast proliferation, ECM remodeling, and biomechanical recovery in collagenous tissue injury.
- Angiogenesis Research: VEGF expression, capillary density, and endothelial tube formation under combined treatment.
- Ischemia-Reperfusion Injury: Cytoprotective and vascular recovery in cardiac, cerebral, and skeletal muscle models.
- IBD Models: Mucosal healing and anti-inflammatory effects in TNBS/DSS-induced colitis.
- Bone and Cartilage Repair: Osteoblast and chondrocyte responses to combined angiogenic and migratory stimulation.
Comparative Context
| Property | BPC-157 Alone | TB-500 Alone | Blend (Synergy) |
|---|---|---|---|
| Angiogenesis | Strong (VEGF/eNOS) | Moderate | Enhanced vascularization |
| Cell Migration | Moderate | Strong (G-actin) | Rapid wound closure |
| Cytoprotection | Strong | Moderate | Broad tissue protection |
Safety & Laboratory Handling
Store lyophilized at -20°C protected from light and moisture. Reconstitute with sterile bacteriostatic water (not included). The blend is pre-mixed — do not attempt to separate components. Reconstituted solutions should be stored at 2-8°C and used within 30 days. Avoid repeated freeze-thaw cycles. Use appropriate PPE. For laboratory research use only.
References
- Staresinic M et al. (2003). “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon.” J Orthop Res. PMID: 14567673.
- Sikiric P et al. (2014). “Stable gastric pentadecapeptide BPC 157.” Curr Pharm Des. PMID: 24588628.
- Goldstein AL et al. (2005). “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med. PMID: 16098866.
- Malinda KM et al. (1999). “Thymosin beta4 accelerates wound healing.” J Invest Dermatol. PMID: 10469335.
- Philp D et al. (2004). “Thymosin beta4 promotes angiogenesis and wound healing.” Mech Ageing Dev. PMID: 14759504.
- Huang GW et al. (2015). “BPC 157 promotes angiogenesis through VEGF-MAPK pathway.” Peptides. PMID: 26471065.
- Sosne G et al. (2007). “Thymosin beta 4 suppression of corneal NFkappaB.” Exp Eye Res. PMID: 17239864.
- Park JM et al. (2020). “BPC 157 rescued NSAID-induced gastrointestinal injury.” Inflammopharmacology. PMID: 31919693.
⚠ Research Use Only: Sold exclusively for in vitro laboratory research. Not FDA-evaluated for human use.
Reviews
There are no reviews yet.